{"protocolSection":{"identificationModule":{"nctId":"NCT03198715","orgStudyIdInfo":{"id":"DS1040-A-J110"},"secondaryIdInfos":[{"id":"173612","type":"REGISTRY","domain":"JAPIC CTI"}],"organization":{"fullName":"Daiichi Sankyo, Inc.","class":"INDUSTRY"},"briefTitle":"Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy","officialTitle":"A Phase I, Single Blind, Placebo-controlled, Randomized Study to Assess the Safety of DS-1040b in Subjects With Thrombectomy Treated Acute Ischemic Stroke."},"statusModule":{"statusVerifiedDate":"2021-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-07-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-01-19","type":"ACTUAL"},"completionDateStruct":{"date":"2020-01-19","type":"ACTUAL"},"studyFirstSubmitDate":"2017-06-19","studyFirstSubmitQcDate":"2017-06-22","studyFirstPostDateStruct":{"date":"2017-06-26","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-01-07","resultsFirstSubmitQcDate":"2021-01-07","resultsFirstPostDateStruct":{"date":"2021-01-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-01-07","lastUpdatePostDateStruct":{"date":"2021-01-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Daiichi Sankyo Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The aim of this study is to find out if DS-1040b is safe and tolerable in acute ischemic stroke patients with thrombectomy. Four groups will receive different doses of DS-1040b by intravenous infusion for 6 hours. Groups with the lowest dose will start. When it is determined that each dose is safe and tolerable, the next higher dose will be given to the next group."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Fibrinolysis enhancer","TAFIa inhibitor","Developmental Phase I"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":42,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"DS-1040b 0.6 mg","type":"EXPERIMENTAL","description":"Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours","interventionNames":["Drug: DS1040b"]},{"label":"DS-1040b 1.2 mg","type":"EXPERIMENTAL","description":"Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours","interventionNames":["Drug: DS1040b"]},{"label":"DS-1040b 2.4 mg","type":"EXPERIMENTAL","description":"Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours","interventionNames":["Drug: DS1040b"]},{"label":"DS-1040b 4.8 mg","type":"EXPERIMENTAL","description":"Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours","interventionNames":["Drug: DS1040b"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants receive saline by intravenous infusion over six hours","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"DS1040b","description":"DS-1040b in solution for intravenous infusion","armGroupLabels":["DS-1040b 0.6 mg","DS-1040b 1.2 mg","DS-1040b 2.4 mg","DS-1040b 4.8 mg"],"otherNames":["Investigational product"]},{"type":"DRUG","name":"Placebo","description":"Saline solution for intravenous infusion","armGroupLabels":["Placebo"],"otherNames":["Saline solution"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Symptomatic or Asymptomatic Intracranial Hemorrhage (ICH) Within 36 Hours From Start of Treatment With DS-1040b in Acute Ischemic Stroke Participants","description":"Symptomatic and asymptomatic intracranial hemorrhage (ICH) confirmed by head imaging (CT or MRI) are reported. Symptomatic ICH was defined as Intracranial hemorrhage with clinical deterioration causing an increase in the National Institutes of Health Stroke Scale (NIHSS) score of ≥ 4 points (defined by European Cooperative Acute Stroke Study). Asymptomatic ICH included the following: Hemorrhagic infarction type 1: Small petechial hemorrhage along the margins of the infarct, Hemorrhagic infarction type 2: Confluent petechial hemorrhage within the infarcted area, but without a mass effect, Parenchymal hematoma type 1: Hematoma involving ≤ 30% of the infarcted area with a slight mass effect, Parenchymal hematoma type 2: Hematoma involving \\> 30% of, or outside the infarcted area, with a significant mass effect.","timeFrame":"From start of treatment up to 36 hours post single, intravenous dose"},{"measure":"Number of Participants With Non-ICH Major Bleeding Within 96 Hours From Start of Treatment With DS-1040b In Acute Ischemic Stroke Participants","description":"Non-ICH was defined as a clinically evident bleeding with a 5 g/dL or greater decrease in hemoglobin.","timeFrame":"From start of treatment up to 96 hours post single, intravenous dose"}],"secondaryOutcomes":[{"measure":"Pharmacokinetic Analysis Area Under The Plasma Concentration Time Curve (AUC) of DS-1040a in Plasma","description":"The pharmacokinetic (PK) parameter of area under the plasma concentration-time curve up to the last quantifiable time was calculated using linear up logarithmic down rule.","timeFrame":"Predose, 0.5 hours (h), 3 h, 6 h, 18 h, 24 h, 48 h, and 96 h post single, intravenous dose"},{"measure":"Pharmacokinetic Analysis Maximum Concentration (Cmax) of DS-1040a in Plasma","description":"The PK parameter of maximum concentration (Cmax) was observed values.","timeFrame":"Predose, 0.5 hours (h), 3 h, 6 h, 18 h, 24 h, 48 h, and 96 h post single, intravenous dose"},{"measure":"Pharmacokinetic Analysis Time to Maximum Concentration (Tmax) of DS-1040b in Plasma","description":"The PK parameter of time to maximum concentration (Tmax) was observed values. When there are more than one time point, the time point when the concentration reached the first Cmax will be used as Tmax.","timeFrame":"Predose, 0.5 hours (h), 3 h, 6 h, 18 h, 24 h, 48 h, and 96 h post single, intravenous dose"},{"measure":"Pharmacokinetic Analysis Terminal Half-Life (T1/2) of DS-1040b in Plasma","description":"The PK parameter of terminal half-life (T1/2) was calculated from the following formula in participants whose Kel could be calculated. T1/2=ln2 / Kel","timeFrame":"Predose, 0.5 hours (h), 3 h, 6 h, 18 h, 24 h, 48 h, and 96 h post single, intravenous dose"},{"measure":"Pharmacokinetic Analysis Mean Amount of DS-1040a Excreted in Urine in Acute Ischemic Stroke Participants","description":"The pharmacokinetic parameter of amount of drug excreted in urine was calculated from the following formula:\n\nurine concentration (ng/mL) /10\\^6× (urine weight / urinary specific gravity)","timeFrame":"From start of treatment up to 24 hours post single, intravenous dose"},{"measure":"Pharmacodynamic Analysis Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Antigen Levels in Plasma and Change From Baseline in Acute Ischemic Stroke Participants","description":"The mean thrombin activatable fibrinolysis (TAFI) antigen levels and change from baseline in TAFI levels are reported. Change from baseline is based on the number of participants with baseline and at least one post-baseline laboratory test.","timeFrame":"Baseline, 6 hours and 24 hours post single, intravenous dose"},{"measure":"Pharmacodynamic Analysis D-dimer Levels in Plasma and Change From Baseline in Acute Ischemic Stroke Participants","description":"Mean D-dimer levels and change from baseline in D-dimer levels are reported.Change from baseline is based on the number of subjects with baseline and at least one post-baseline laboratory test.","timeFrame":"Baseline, 6 hours, 24 hours, and 48 hours post single, intravenous dose"},{"measure":"Pharmacodynamic Analysis Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) Activity and Change From Baseline in Acute Ischemic Stroke Participants","description":"Mean activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) and change from baseline in TAFIa are reported. Change from baseline is based on the number of subjects with baseline and at least one post-baseline laboratory test.","timeFrame":"Baseline, 6 hours, 24 hours, and 48 hours post single, intravenous dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is an acute ischemic stroke patients with evidence of intracranial vascular occlusion\n* Is enrolled in principle within 8 hours of symptom onset\n* Has treatment plan that includes stent retriever\n* Has protocol-defined scores on several scales\n\nExclusion Criteria:\n\n* Has treatment plan that includes fibrinolysis or fibinolysis\n* Has identified intracranial hemorrhage or subarachnoid hemorrhage\n* Has active bleeding like gastrointestinal hemorrhage\n* Has cerebral bleeding risk; intracranial tumor, brain aneurysm, cerebral arteriovenous malformation, or history of intracranial bleeding\n* Has severe hepatic or renal impairment\n* Has been a participant in other clinical trial within 30 days prior to treatment\n* Is pregnant, lactating, or planning on becoming pregnant during treatment period\n* Has any condition or history that might, per protocol or in the opinion of the investigator, compromise:\n\n  1. safety or well-being of the participant or their offspring\n  2. safety of the study staff\n  3. analysis of results","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"89 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Global Clinical Leader","affiliation":"Daiichi Sankyo, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Hirosaki University Hospital","city":"Hirosaki","state":"Aomori","zip":"036-8563","country":"Japan","geoPoint":{"lat":40.59306,"lon":140.4725}},{"facility":"Funabashi Municipal Medical Center","city":"Funabashi","state":"Chiba","zip":"273-8588","country":"Japan","geoPoint":{"lat":35.70129,"lon":139.98648}},{"facility":"Kokura Memorial Hospital","city":"Kitakyushu","state":"Fukuota","zip":"802-8555","country":"Japan","geoPoint":{"lat":33.85181,"lon":130.85034}},{"facility":"Mihara Memorial Hospital","city":"Isesaki","state":"Gunma","zip":"372-0006","country":"Japan","geoPoint":{"lat":36.31667,"lon":139.2}},{"facility":"Nakamura Memorial Hospital","city":"Sapporo","state":"Hokkaido","zip":"060-8570","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Japan Organization of Occupational Health and Safety Kansai Rosai Hospital","city":"Amagasaki","state":"Hyogo","zip":"660-8511","country":"Japan","geoPoint":{"lat":34.71667,"lon":135.41667}},{"facility":"Kobe City Medical Center General Hospital","city":"Kobe","state":"Hyogo","zip":"650-0046","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Hyogo College of Medicine College Hospital","city":"Nishinomiya","state":"Hyogo","zip":"663-8501","country":"Japan","geoPoint":{"lat":34.71562,"lon":135.33199}},{"facility":"University of Tsukuba Hospital","city":"Tsukuba","state":"Ibaraki","zip":"305-8576","country":"Japan","geoPoint":{"lat":36.2,"lon":140.1}},{"facility":"Iwate Prefectural Central Hospital","city":"Morioka","state":"Iwate","zip":"020-0066","country":"Japan","geoPoint":{"lat":39.7,"lon":141.15}},{"facility":"Seisho Hospital","city":"Odawara","state":"Kanagawa","zip":"250-0001","country":"Japan","geoPoint":{"lat":35.25556,"lon":139.15972}},{"facility":"Yokohama Municipal Citizen's Hospital","city":"Yokohama","state":"Kanagawa","zip":"240-8555","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Mie University Hospital","city":"Tsu","state":"Mie","zip":"514-8507","country":"Japan","geoPoint":{"lat":34.73333,"lon":136.51667}},{"facility":"National Cerebral and Cardiovascular Center","city":"Suita","state":"Osaka","zip":"565-8565","country":"Japan","geoPoint":{"lat":34.76143,"lon":135.51567}},{"facility":"Saitama Medical University International Medical Center","city":"Hidaka","state":"Saitama","zip":"350-1298","country":"Japan"},{"facility":"Yamaguchi University Hospital","city":"Ube","state":"Yamaguchi","zip":"755-8505","country":"Japan","geoPoint":{"lat":33.94306,"lon":131.25111}},{"facility":"Hiroshima City Hiroshima Citizens Hospital","city":"Hiroshima","zip":"730-8518","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"Nagasaki University Hospital","city":"Nagasaki","zip":"852-8521","country":"Japan","geoPoint":{"lat":32.75,"lon":129.88333}},{"facility":"Niigata City General Hospital","city":"Niigata","zip":"950-1197","country":"Japan","geoPoint":{"lat":37.88637,"lon":139.00589}},{"facility":"Wakayama Medical University Hospital","city":"Wakayama","zip":"641-8509","country":"Japan","geoPoint":{"lat":34.23333,"lon":135.16667}}]},"referencesModule":{"references":[{"pmid":"35061236","type":"DERIVED","citation":"Sakai N, Takeuchi M, Imamura H, Shimamura N, Yoshimura S, Naito H, Kimura N, Masuo O, Hirotsune N, Morita K, Toyoda K, Yamagami H, Ishihara H, Nakatsu T, Miyoshi N, Suda M, Fujimoto S. Safety, Pharmacokinetics and Pharmacodynamics of DS-1040, in Combination with Thrombectomy, in Japanese Patients with Acute Ischemic Stroke. Clin Drug Investig. 2022 Feb;42(2):137-149. doi: 10.1007/s40261-021-01112-8. Epub 2022 Jan 21."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"The study consisted of 4 parallel, ascending-dose cohorts. The DS-1040b 0.6 mg cohort only consisted of a DS-1040b group. A ratio of DS-1040b:placebo of 3:1 per cohort was used for the 1.2 mg and higher dose cohorts.","recruitmentDetails":"A total of 42 participants who met all inclusion criteria and no exclusion criteria were randomized to treatment. Of the 42 participants randomized, 41 participants received treatment.","groups":[{"id":"FG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"FG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"FG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"FG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."},{"id":"FG004","title":"Placebo","description":"Participants who received a single, intravenous infusion of placebo."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"9"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Demographics and baseline characteristics were assessed in the Safety Analysis Set.","groups":[{"id":"BG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"BG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"BG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"BG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."},{"id":"BG004","title":"Placebo","description":"Participants who received a single, intravenous infusion of placebo."},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"41"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"6"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"35"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71.5","spread":"6.80"},{"groupId":"BG001","value":"76.3","spread":"6.96"},{"groupId":"BG002","value":"73.6","spread":"10.40"},{"groupId":"BG003","value":"69.0","spread":"7.81"},{"groupId":"BG004","value":"76.9","spread":"11.22"},{"groupId":"BG005","value":"74.5","spread":"8.97"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"19"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"22"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"41"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"41"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Japan","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"41"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Symptomatic or Asymptomatic Intracranial Hemorrhage (ICH) Within 36 Hours From Start of Treatment With DS-1040b in Acute Ischemic Stroke Participants","description":"Symptomatic and asymptomatic intracranial hemorrhage (ICH) confirmed by head imaging (CT or MRI) are reported. Symptomatic ICH was defined as Intracranial hemorrhage with clinical deterioration causing an increase in the National Institutes of Health Stroke Scale (NIHSS) score of ≥ 4 points (defined by European Cooperative Acute Stroke Study). Asymptomatic ICH included the following: Hemorrhagic infarction type 1: Small petechial hemorrhage along the margins of the infarct, Hemorrhagic infarction type 2: Confluent petechial hemorrhage within the infarcted area, but without a mass effect, Parenchymal hematoma type 1: Hematoma involving ≤ 30% of the infarcted area with a slight mass effect, Parenchymal hematoma type 2: Hematoma involving \\> 30% of, or outside the infarcted area, with a significant mass effect.","populationDescription":"Bleeding events were assessed in the Safety Analysis Set.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From start of treatment up to 36 hours post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."},{"id":"OG004","title":"Placebo","description":"Participants who received a single, intravenous infusion of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"9"}]}],"classes":[{"title":"Symptomatic ICH","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Asymptomatic ICH","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}]},{"title":"Hemorrhagic infarction type 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Hemorrhagic infarction type 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Parenchymal hematoma type 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]},{"title":"Parenchymal hematoma type 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Not applicable","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Non-ICH Major Bleeding Within 96 Hours From Start of Treatment With DS-1040b In Acute Ischemic Stroke Participants","description":"Non-ICH was defined as a clinically evident bleeding with a 5 g/dL or greater decrease in hemoglobin.","populationDescription":"Bleeding events were assessed in the Safety Analysis Set.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From start of treatment up to 96 hours post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."},{"id":"OG004","title":"Placebo","description":"Participants who received a single, intravenous infusion of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Analysis Area Under The Plasma Concentration Time Curve (AUC) of DS-1040a in Plasma","description":"The pharmacokinetic (PK) parameter of area under the plasma concentration-time curve up to the last quantifiable time was calculated using linear up logarithmic down rule.","populationDescription":"Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng*h/mL","timeFrame":"Predose, 0.5 hours (h), 3 h, 6 h, 18 h, 24 h, 48 h, and 96 h post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":"45.5"},{"groupId":"OG001","value":"275","spread":"72.2"},{"groupId":"OG002","value":"570","spread":"230"},{"groupId":"OG003","value":"1550","spread":"962"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Analysis Maximum Concentration (Cmax) of DS-1040a in Plasma","description":"The PK parameter of maximum concentration (Cmax) was observed values.","populationDescription":"Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Predose, 0.5 hours (h), 3 h, 6 h, 18 h, 24 h, 48 h, and 96 h post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":"6.25"},{"groupId":"OG001","value":"29.7","spread":"7.50"},{"groupId":"OG002","value":"60.6","spread":"11.8"},{"groupId":"OG003","value":"141","spread":"61.7"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Analysis Time to Maximum Concentration (Tmax) of DS-1040b in Plasma","description":"The PK parameter of time to maximum concentration (Tmax) was observed values. When there are more than one time point, the time point when the concentration reached the first Cmax will be used as Tmax.","populationDescription":"Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"hours","timeFrame":"Predose, 0.5 hours (h), 3 h, 6 h, 18 h, 24 h, 48 h, and 96 h post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":"2.18"},{"groupId":"OG001","value":"4.67","spread":"2.29"},{"groupId":"OG002","value":"5.11","spread":"1.85"},{"groupId":"OG003","value":"5.96","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Analysis Terminal Half-Life (T1/2) of DS-1040b in Plasma","description":"The PK parameter of terminal half-life (T1/2) was calculated from the following formula in participants whose Kel could be calculated. T1/2=ln2 / Kel","populationDescription":"Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis set in participants with available sample for analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"hours","timeFrame":"Predose, 0.5 hours (h), 3 h, 6 h, 18 h, 24 h, 48 h, and 96 h post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.61"},{"groupId":"OG001","value":"16.8","spread":"1.74"},{"groupId":"OG002","value":"19.5","spread":"10.5"},{"groupId":"OG003","value":"29.7","spread":"2.35"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Analysis Mean Amount of DS-1040a Excreted in Urine in Acute Ischemic Stroke Participants","description":"The pharmacokinetic parameter of amount of drug excreted in urine was calculated from the following formula:\n\nurine concentration (ng/mL) /10\\^6× (urine weight / urinary specific gravity)","populationDescription":"Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set in participants with available sample for analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg","timeFrame":"From start of treatment up to 24 hours post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.420","spread":"0.0308"},{"groupId":"OG001","value":"0.880","spread":"0.0683"},{"groupId":"OG002","value":"1.49","spread":"0.309"},{"groupId":"OG003","value":"3.45","spread":"0.417"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamic Analysis Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Antigen Levels in Plasma and Change From Baseline in Acute Ischemic Stroke Participants","description":"The mean thrombin activatable fibrinolysis (TAFI) antigen levels and change from baseline in TAFI levels are reported. Change from baseline is based on the number of participants with baseline and at least one post-baseline laboratory test.","populationDescription":"Pharmacodynamic parameters were assessed in the Pharmacodynamic Analysis Set.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"% of normal pooled plasma control","timeFrame":"Baseline, 6 hours and 24 hours post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."},{"id":"OG004","title":"Placebo","description":"Participants who received a single, intravenous infusion of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.17","spread":"25.527"},{"groupId":"OG001","value":"80.05","spread":"9.101"},{"groupId":"OG002","value":"79.56","spread":"19.553"},{"groupId":"OG003","value":"81.90","spread":"2.750"},{"groupId":"OG004","value":"88.28","spread":"17.157"}]}]},{"title":"6 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.05","spread":"22.090"},{"groupId":"OG001","value":"81.37","spread":"11.358"},{"groupId":"OG002","value":"86.12","spread":"13.727"},{"groupId":"OG003","value":"81.23","spread":"6.313"},{"groupId":"OG004","value":"87.55","spread":"15.987"}]}]},{"title":"24 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.75","spread":"20.938"},{"groupId":"OG001","value":"78.09","spread":"11.033"},{"groupId":"OG002","value":"77.62","spread":"14.208"},{"groupId":"OG003","value":"72.70","spread":"8.681"},{"groupId":"OG004","value":"79.11","spread":"13.051"}]}]},{"title":"Change from baseline to 6 hour postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"6.463"},{"groupId":"OG001","value":"1.69","spread":"5.077"},{"groupId":"OG002","value":"1.28","spread":"8.551"},{"groupId":"OG003","value":"-0.67","spread":"4.202"},{"groupId":"OG004","value":"-0.73","spread":"5.579"}]}]},{"title":"Change from baseline to 24 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.42","spread":"6.934"},{"groupId":"OG001","value":"-1.95","spread":"9.641"},{"groupId":"OG002","value":"-5.09","spread":"6.625"},{"groupId":"OG003","value":"-9.20","spread":"6.070"},{"groupId":"OG004","value":"-9.16","spread":"9.759"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamic Analysis D-dimer Levels in Plasma and Change From Baseline in Acute Ischemic Stroke Participants","description":"Mean D-dimer levels and change from baseline in D-dimer levels are reported.Change from baseline is based on the number of subjects with baseline and at least one post-baseline laboratory test.","populationDescription":"Pharmacodynamic parameters were assessed in the Pharmacodynamic Analysis Set.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ug/mL FEU","timeFrame":"Baseline, 6 hours, 24 hours, and 48 hours post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."},{"id":"OG004","title":"Placebo","description":"Participants who received a single, intravenous infusion of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.600","spread":"2.8865"},{"groupId":"OG001","value":"0.730","spread":"0.4176"},{"groupId":"OG002","value":"2.423","spread":"4.8964"},{"groupId":"OG003","value":"0.613","spread":"0.1250"},{"groupId":"OG004","value":"3.096","spread":"6.8343"}]}]},{"title":"6 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.368","spread":"2.1428"},{"groupId":"OG001","value":"0.717","spread":"0.4899"},{"groupId":"OG002","value":"3.254","spread":"6.3573"},{"groupId":"OG003","value":"1.090","spread":"0.4540"},{"groupId":"OG004","value":"3.436","spread":"7.3095"}]}]},{"title":"24 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.158","spread":"1.6216"},{"groupId":"OG001","value":"0.960","spread":"0.7254"},{"groupId":"OG002","value":"2.879","spread":"6.0571"},{"groupId":"OG003","value":"1.067","spread":"0.5235"},{"groupId":"OG004","value":"3.731","spread":"7.1964"}]}]},{"title":"48 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.907","spread":"1.1908"},{"groupId":"OG001","value":"0.912","spread":"0.5107"},{"groupId":"OG002","value":"2.668","spread":"6.0954"},{"groupId":"OG003","value":"1.287","spread":"0.7371"},{"groupId":"OG004","value":"0.941","spread":"0.5545"}]}]},{"title":"Change from baseline to 6 hour postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.452","spread":"1.0327"},{"groupId":"OG001","value":"-0.008","spread":"0.1091"},{"groupId":"OG002","value":"1.497","spread":"2.6031"},{"groupId":"OG003","value":"0.477","spread":"0.5742"},{"groupId":"OG004","value":"-0.023","spread":"0.1340"}]}]},{"title":"Change from baseline to 24 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.442","spread":"1.2701"},{"groupId":"OG001","value":"0.217","spread":"0.5241"},{"groupId":"OG002","value":"1.180","spread":"2.4023"},{"groupId":"OG003","value":"0.453","spread":"0.6422"},{"groupId":"OG004","value":"0.284","spread":"0.4342"}]}]},{"title":"Change from baseline to 48 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.693","spread":"1.6989"},{"groupId":"OG001","value":"0.163","spread":"0.2431"},{"groupId":"OG002","value":"1.033","spread":"2.4047"},{"groupId":"OG003","value":"0.673","spread":"0.8559"},{"groupId":"OG004","value":"0.260","spread":"0.4700"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamic Analysis Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) Activity and Change From Baseline in Acute Ischemic Stroke Participants","description":"Mean activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) and change from baseline in TAFIa are reported. Change from baseline is based on the number of subjects with baseline and at least one post-baseline laboratory test.","populationDescription":"Pharmacodynamic parameters were assessed in the Pharmacodynamic Analysis Set.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"% of normal pooled plasma control","timeFrame":"Baseline, 6 hours, 24 hours, and 48 hours post single, intravenous dose","groups":[{"id":"OG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg."},{"id":"OG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg."},{"id":"OG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg."},{"id":"OG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg."},{"id":"OG004","title":"Placebo","description":"Participants who received a single, intravenous infusion of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"104.5","spread":"30.68"},{"groupId":"OG001","value":"81.8","spread":"17.67"},{"groupId":"OG002","value":"93.9","spread":"28.92"},{"groupId":"OG003","value":"99.0","spread":"8.54"},{"groupId":"OG004","value":"88.7","spread":"18.99"}]}]},{"title":"6 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110.4","spread":"28.10"},{"groupId":"OG001","value":"77.9","spread":"18.52"},{"groupId":"OG002","value":"82.7","spread":"16.49"},{"groupId":"OG003","value":"68.7","spread":"10.97"},{"groupId":"OG004","value":"95.5","spread":"21.63"}]}]},{"title":"24 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.4","spread":"29.03"},{"groupId":"OG001","value":"78.7","spread":"14.58"},{"groupId":"OG002","value":"90.7","spread":"18.67"},{"groupId":"OG003","value":"91.7","spread":"7.51"},{"groupId":"OG004","value":"88.0","spread":"16.00"}]}]},{"title":"48 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":"27.01"},{"groupId":"OG001","value":"70.0","spread":"7.09"},{"groupId":"OG002","value":"84.7","spread":"17.50"},{"groupId":"OG003","value":"88.7","spread":"6.66"},{"groupId":"OG004","value":"87.6","spread":"13.96"}]}]},{"title":"Change from baseline to 6 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"11.04"},{"groupId":"OG001","value":"-2.6","spread":"11.82"},{"groupId":"OG002","value":"-14.6","spread":"16.00"},{"groupId":"OG003","value":"-30.3","spread":"13.01"},{"groupId":"OG004","value":"8.0","spread":"13.24"}]}]},{"title":"Change from baseline to 24 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"7.56"},{"groupId":"OG001","value":"-5.5","spread":"15.17"},{"groupId":"OG002","value":"-6.4","spread":"12.03"},{"groupId":"OG003","value":"-7.3","spread":"16.04"},{"groupId":"OG004","value":"0.6","spread":"8.00"}]}]},{"title":"Change from baseline to 48 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.3","spread":"9.99"},{"groupId":"OG001","value":"-6.9","spread":"11.46"},{"groupId":"OG002","value":"-11.0","spread":"10.92"},{"groupId":"OG003","value":"-10.3","spread":"13.61"},{"groupId":"OG004","value":"-1.1","spread":"13.95"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Treatment-emergent adverse event (TEAE) data were collected from start of treatment up to 30 days after last study dose, up to approximately 2 years 6 months.","description":"A TEAE is defined as an adverse event (AE) that is not present prior to the study and occurs after the start of study drug administration but before Day 30, or an AE that worsens in severity after the start of study drug administration but before Day 30.","eventGroups":[{"id":"EG000","title":"DS-1040b 0.6 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 0.6 mg.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":5,"otherNumAtRisk":6},{"id":"EG001","title":"DS-1040b 1.2 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 1.2 mg.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":2,"seriousNumAtRisk":12,"otherNumAffected":10,"otherNumAtRisk":12},{"id":"EG002","title":"DS-1040b 2.4 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 2.4 mg.","deathsNumAffected":1,"deathsNumAtRisk":11,"seriousNumAffected":2,"seriousNumAtRisk":11,"otherNumAffected":10,"otherNumAtRisk":11},{"id":"EG003","title":"DS-1040b 4.8 mg","description":"Participants who received a single, intravenous infusion of DS-1040b 4.8 mg.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":2,"otherNumAtRisk":3},{"id":"EG004","title":"Placebo","description":"Participants who received a single, intravenous infusion of placebo.","deathsNumAffected":2,"deathsNumAtRisk":9,"seriousNumAffected":1,"seriousNumAtRisk":9,"otherNumAffected":8,"otherNumAtRisk":9}],"seriousEvents":[{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]}],"otherEvents":[{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":9}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":9}]},{"term":"Periodontis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Respiratory moniliasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Metastases to lymph nodes","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Metastases to peritoneum","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Haemorrhagic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Carotid artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Cerebral artery embolism","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Cervicobrachial syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Neurological symptom","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Parkinsonism","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Eye discharge","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Haemorrhagic infarction","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":5,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Internal haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Apnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Pharyngeal haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Respiratory tract haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":3,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":3,"numAtRisk":9}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Acetonaemic vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Lip haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Mouth haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Proctitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Liver disorder","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Dermatitis diaper","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":9}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Purpura","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Haemorrhage urinary tract","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Neurogenic bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Renal disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Vessel puncture site haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Puncture site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Vessel puncture site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Blood phosphorus decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"ECG signs of myocardial ischaemia","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Liver function test increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Subcutaneous haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":2,"numAtRisk":9}]},{"term":"Pharyngeal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Urethral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":9}]},{"term":"Urinary tract injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]},{"term":"Wound haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":9}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Contact for Clinical Trial Information","organization":"Daiichi Sankyo","email":"CTRinfo@dsi.com","phone":"908-992-6400"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2019-04-17","uploadDate":"2021-01-07T18:02","filename":"Prot_SAP_000.pdf","size":19284945}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}